http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006519018-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-00 |
| filingDate | 2004-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006519018-A |
| titleOfInvention | Clinically significant animal model of human breast cancer and VEGF involvement in fibrosis |
| abstract | VEGF expression is associated with clinically aggressive, tamoxifen-resistant metastatic breast cancer. To investigate the role of VEGF expression in breast cancer growth, metastasis and development of anti-estrogen resistance and fibrosis, several ER-positive MCF-7-derived cell lines, C9V, were expressed to express VEGF under doxycycline control. Operated. To create a breast cancer xenograft model, C9V cells were introduced into athymic nude mice. Expression of VEGF in xenografts activated angiogenesis, promoted tumor growth, stimulated tamoxifen-resistant phenotype, increased potential metastatic potential, and induced fibrogenic response. These results suggest that suppression of VEGF expression or action is effective for breast cancer treatment. Furthermore, suppression of VEGF expression or action by suppression of estrogen expression or action may also be effective. |
| priorityDate | 2003-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 323.